학술논문
A phase III trial of melphalan/prednisone/lenalidomide (MPR) versus melphalan (200 mg/m(2)) and autologous transplantation (MEL200) in newly diagnosed myeloma patients
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15277755